How much funding has VarmX raised?

VarmX has raised $100.7M in total funding, most recently a Grant round.

Who are VarmX's investors?

VarmX's investors include European Innovation Council Fund, Ysios Capital, Sound Bioventures, Lundbeckfonden Ventures, BioGeneration Ventures.

Where is VarmX headquartered?

VarmX is headquartered in Leiden, Netherlands.

What industry is VarmX in?

VarmX operates in Biotech, Healthcare.

VarmX

Restoring blood coagulation in patients taking Factor Xa Direct Oral Anticoagulants

Leiden, Netherlands · Founded 2016 · $100.7M raised

Biotech

Healthcare

Headquarters: Leiden
Employees: 11–50
Founded: 2016
Business Model: B2B

Website: varmx.com
Total Funding: $100.7M
Last Round: $16.5M GrantFeb 2025
Rounds: 5

About

VarmX is a clinical-stage biotech company founded in 2016 as a spin-off from Leiden University Medical Center (LUMC), focused on developing a universal bypassing agent to restore blood coagulation in patients taking Factor Xa Direct Oral Anticoagulants (FXa-DOACs). Its lead asset VMX-C001 targets severe bleeding events and surgical bleeding risk in patients on FXa-DOACs, a growing patient population with limited reversal options. The company has completed a €32M Series B financing and is preparing for a global Phase III pivotal trial.

Summary

VarmX is a Biotech company based in Leiden, Netherlands, founded in 2016. It has raised $100.7M in total across 5 rounds, most recently a $16.5M Grant round in Feb 2025. Investors include European Innovation Council Fund, Ysios Capital and Sound Bioventures.